menu
    • menu

    Company profile for Fishfa Biogenics

    Fishfa Biogenics-PSE
    News
    Beyond the Label What Defines Pharma-Grade Mupirocin Calcium API

    30 Jan 2026

    // PRESS RELEASE

    The Market Is Correcting Itself-Only High-Consistency Mupirocin

    12 Jan 2026

    // PRESS RELEASE

    The API Race Is On — And Fishfa Biogenics Is Setting the Pace!

    06 Nov 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Fishfa Biogenics

    Contact Supplier

    Website

    BPI Europe

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/kMLUFIe3emo

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Related CompaniesRelated Companies

    About

    Fishfa Biogenics, a division of Fishfa Rubbers Ltd., manufactures and supplies biological APIs. The company operates GLP labs and WHO-GMP-certified facilities, specializing in fermentation-based production, process development, and manufacturing. Its site includes microbial drug substance production, quality testing, and technical, regulatory, and IP support. Fishfa exports APIs such as Mupirocin and Tacrolimus to markets in Europe, Asia, the Middle East, South America, Russia, New Zealand, and the UK. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Fishfa Biogenicsindia-flag Flag
    Country
    Country
    India
    Address
    Address
    Survey No. 43/2/2, 47/2, 50/1/2, 50/2, Kuwadva Wankaner Road, Surya Rampara - ...
    Telephone
    Telephone
    +91 9099050697
    Client Email
    Email
    marketing@fishfabiogenics.com
    Client Website
    Website
    https://www.fishfabiogenics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/in/FishfaBiogenics/
    youtube
    YouTube
    http://www.youtube.com/@fishfabiogenics1272
    Twitter
    Twitter
    https://x.com/FishfaBiogenics
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/fishfa-biogenics-party-content-89587.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/fishfa-biogenics-party-content-27131.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/fishfa-biogenics-party-content-66322.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Products Under Development 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/fishfa-biogenics-party-content-59934.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4192

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

    #PharmaFlow by PHARMACOMPASS
    13 Nov 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Beyond the Label What Defines Pharma-Grade Mupirocin Calcium API
    Beyond the Label What Defines Pharma-Grade Mupirocin Calcium API

    30 Jan 2026

    // PRESS RELEASE

    https://www.fishfabiogenics.com/mupirocin-calcium/beyond-the-label-what-defines-pharmaceutical-grade-mupirocin-calcium-api/

    PRESS RELEASE
    30 Jan 2026
    Share Share
    The Market Is Correcting Itself-Only High-Consistency Mupirocin
    The Market Is Correcting Itself-Only High-Consistency Mupirocin

    12 Jan 2026

    // PRESS RELEASE

    https://www.fishfabiogenics.com/pharma-api/the-market-is-correcting-itself-only-high-consistency-mupirocin-api-will-survive/

    PRESS RELEASE
    12 Jan 2026
    Share Share
    The API Race Is On — And Fishfa Biogenics Is Setting the Pace!
    The API Race Is On — And Fishfa Biogenics Is Setting the Pace!

    06 Nov 2025

    // PRESS RELEASE

    https://www.fishfabiogenics.com/pharma-api/the-api-race-is-on-and-fishfa-biogenics-is-setting-the-pace/

    PRESS RELEASE
    06 Nov 2025
    Share Share
    Fishfa Biogenics Achieves CEP for Tacrolimus Monohydrate
    Fishfa Biogenics Achieves CEP for Tacrolimus Monohydrate

    25 Sep 2025

    // PRESS RELAESE

    https://www.fishfabiogenics.com/tacrolimus-api/cep-certified-tacrolimus-api-monohydrate/

    PRESS RELAESE
    25 Sep 2025
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company
    Fishfa Biogenics

    ABOUT THIS PAGE

    Contact Fishfa Biogenics and get a quotation

    Fishfa Biogenics is a supplier offers 19 products (APIs, Excipients or Intermediates).

    Find Tacrolimus bulk with CEP offered by Fishfa Biogenics

    Find Mupirocin Calcium bulk with DMF offered by Fishfa Biogenics

    Find Cyclosporine bulk with DMF offered by Fishfa Biogenics

    Find Tacrolimus bulk with DMF offered by Fishfa Biogenics

    Find Mupirocin bulk offered by Fishfa Biogenics

    Find Anidulafungin bulk offered by Fishfa Biogenics

    Find Caspofungin bulk offered by Fishfa Biogenics

    Find Daptomycin bulk offered by Fishfa Biogenics

    Find Everolimus bulk offered by Fishfa Biogenics

    Find Micafungin bulk offered by Fishfa Biogenics

    Find Mitomycin bulk offered by Fishfa Biogenics

    Find Mycophenolate Mofetil bulk offered by Fishfa Biogenics

    Find Mycophenolate Sodium bulk offered by Fishfa Biogenics

    Find Nystatin bulk offered by Fishfa Biogenics

    Find Pimecrolimus bulk offered by Fishfa Biogenics

    Find Polymyxin B Sulfate bulk offered by Fishfa Biogenics

    Find Sirolimus bulk offered by Fishfa Biogenics

    Find Teicoplanin bulk offered by Fishfa Biogenics

    Find Temsirolimus bulk offered by Fishfa Biogenics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search